Fredrik Frejd
Chief Scientific Officer Affibody AB
Fredrik Frejd is the Chief Scientific Officer at Affibody and has over 25 years of experience in life science research with particular expertise in biologics drug development, phage display and therapeutic protein engineering of alternative scaffolds. Dr. Frejd received his Ph.D. from the Swiss Federal Institute of technology, ETH, in Zurich in 2001 and joined Affibody AB in 2002. Fredrik is an adjunct Professor at the Department of Immunology, Genetics and Pathology, Uppsala University with a special focus on development of tumor targeting agents for molecular radiotherapy with more than 95 publications. Dr. Frejd is a Board Director of Mergus development AB, Akiram Therapeutics AB, Immuneed AB, and Deputy Board Director of Amylonix AB.
Seminars
- Leveraging Affibody molecules to target HER2, HER3, B7-H3 and other emerging oncology targets
- Expanding RLTs into breast, gastric, ovarian, lung and other solid tumours through improved tumour penetration
- Selecting the optimal targeting scaffold for challenging tumour biology
- Translating novel targets into clinically viable radiopharmaceutical programmes
